Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 1.00 |
| ▸ | OPRL1 | P41146 | 5/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
| ▸ | DRD4 | P21917 | 3/20 | 0.53 |
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | DRD3 | P35462 | 2/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14280698 | 0.86 | OPRL1 (0.76) | OPRM1OPRL1OPRK1MEN1KMT2A | |
| SCHEMBL14280718 | 0.80 | OPRL1 (0.88) | OPRM1OPRL1OPRK1CTSSDRD4 | |
| SCHEMBL14280695 | 0.79 | OPRM1 (0.65) | OPRM1OPRL1OPRK1MEN1KMT2A | |
| SCHEMBL14280710 | 0.78 | OPRM1 (1.00) | OPRM1OPRL1OPRK1CTSSDRD4 | |
| SCHEMBL14430060 | 0.77 | OPRL1 (0.65) | OPRM1OPRL1OPRK1KMT2ACTSS | |
| SCHEMBL14280697 | 0.77 | OPRL1 (1.00) | OPRM1OPRL1OPRK1CTSSHSD11B1 | |
| SCHEMBL27780012 | 0.77 | OPRL1 (1.00) | OPRM1OPRL1OPRK1CTSSHSD11B1 | |
| SCHEMBL14280672 | 0.76 | OPRM1 (1.00) | OPRM1OPRL1OPRK1MEN1KMT2A | |
| SCHEMBL16719380 | 0.76 | OPRL1 (0.64) | OPRM1OPRL1OPRK1KMT2AHSD11B1 | |
| SCHEMBL25787927 | 0.76 | OPRL1 (0.65) | OPRM1OPRL1OPRK1CTSSHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101541765-A | 3-piperidin-4-yl-indole ORL-1 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-23 | — | — | CN | disclosed |
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
| WO-2007050381-A2 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | OGFRL1, OPRL1, ORMDL3 | OPRM1 11/4885OPRL1 2/4885OPRK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.